Miller

Home

About

Miller Laboratory

Multiscale Network Biology

The lab uses computational and experimental methods to understand how mammalian cell signaling and regulation integrate across multiple scales, from the molecular to whole-body level. We combine multiplexed measurements with in vivo imaging and systems-level mathematical modeling to distill principles of cellular communication. We particularly focus on inflammation and cancer, where abnormal signals in multiple cell types promote disease progression and are therapeutically targeted.

We pursue several major goals:

Key approaches include the following:

Our interdisciplinary approach benefits from close collaboration — including with other groups in CSB — to successfully marry computational analyses with appropriate experimental measurements and models of disease.

Recent Publications (more...)

Kim HY, Li R, Ng TSC, Courties G, Rodell CB, Prytyskach M, Kohler RH, Pittet M, Nahrendorf M, Weissleder R, Miller MA
Quantitative Imaging of Tumor Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin.
ACS Nano. 2018;:ePub - PMID: 30508377 - DOI: 10.1021/acsnano.8b04338
Pineda JJ, Miller MA, Song Y, Kuhn H, Mikula H, Tallapragada N, Weissleder R, Mitchison TJ
Site occupancy calibration of taxane pharmacology in live cells and tissues
Proc Natl Acad Sci U S A. 2018;115(48):E11406-E11414 - PMID: 30429313 - PMCID: PMC6275538 - DOI: 10.1073/pnas.1800047115
Miller MA
Gold photothermal therapy: A positive for negative margins
Sci Transl Med. 2018;10(423):eaar7512 - DOI: 10.1126/scitranslmed.aar7512
Ng EX, Sun G, Wei SC, Miller MA, Dasgupta R, Lam PYP, Chen CH
Ultrafast Single-Cell Level Enzymatic Tumor Profiling.
Anal Chem. 2018;:ePub - PMID: 30362713 - DOI: 10.1021/acs.analchem.8b02576

Recent News (more...)

2017-08-10: CSB has been named as one of the NCI Innovative Research in Cancer Nanotechnology (IRCNs). The IRCNs engage in directed, product-focused research that aims to translate cutting-edge science and technology into the next generation of diagnostic and therapeutic tools. These platforms serve as the core technologies for a wide array of specific applications that will ultimately benefit cancer patients.
2017-02-09: Miles Miller, PhD and Kevin King, MD, PhD have been selected to serve as Associate Scientific Advisors (ASAs) for Science's sister journal, Science Translational Medicine, for 2017-2018.